Shares of AstraZeneca PLC (AZN) surged 5.03% in pre-market trading on Thursday, following the company's impressive fourth-quarter results and optimistic guidance for 2025.
AstraZeneca reported a 24% year-over-year increase in total revenue for Q4 2024, reaching $14.89 billion, driven by robust growth across its key therapy areas, including Oncology (up 27%), Cardiovascular, Renal, and Metabolism (CVRM, up 16%), and Respiratory & Immunology (R&I, up 27%). The company's core earnings per share (EPS) jumped 44% to $2.09, surpassing analysts' expectations.
For the full year 2024, AstraZeneca's total revenue grew 21% to $54.07 billion, while core EPS increased 19% to $8.21. The strong performance was fueled by a 19% rise in product sales, continued growth in partnered medicines (Alliance Revenue), and the achievement of sales-based milestones (Collaboration Revenue).
Looking ahead, AstraZeneca provided an optimistic guidance for 2025, forecasting a high single-digit percentage increase in total revenue and a low double-digit percentage growth in core EPS, both at constant exchange rates. The company also announced plans to increase its annual dividend to $3.20 per share and boost capital expenditure by approximately 50% to support portfolio growth and build capacity for transformative technologies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.